Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-23T15:59:28.690Z Has data issue: false hasContentIssue false

Cardiovascular risk in patients with severe mental illness in Italy

Published online by Cambridge University Press:  26 October 2020

Virginio Salvi*
Affiliation:
Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy
Andrea Aguglia
Affiliation:
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Francesco Barone-Adesi
Affiliation:
Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Davide Bianchi
Affiliation:
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Chiara Donfrancesco
Affiliation:
Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy
Filippo Dragogna
Affiliation:
Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy
Luigi Palmieri
Affiliation:
Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy
Gianluca Serafini
Affiliation:
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Mario Amore
Affiliation:
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Claudio Mencacci
Affiliation:
Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy
*
*Virginio Salvi, E-mail: [email protected]

Abstract

Background

Patients with severe mental illness (SMI), such as schizophrenia or bipolar disorders, are more frequently affected by metabolic syndrome and cardiovascular (CV) diseases than the general population, with a significant reduction in life expectancy. Beyond metabolic syndrome, quantifying the risk of CV morbidity in the long-term may help clinicians to put in place preventive strategies. In this study, we assessed 10-year CV risk in patients with SMI and healthy individuals using an algorithm validated on the Italian general population.

Methods

Patients aged 35–69 years diagnosed with SMI were consecutively recruited from psychiatric acute care units. Single CV risk factors were assessed, and 10-year CV risk calculated by means of the CUORE Project 10-year CV risk algorithm, based on the combination of the following risk factors: age, systolic blood pressure, total and high-density lipoprotein cholesterol, diabetes, smoking habit, and hypertensive treatment. Patients’ data were compared with those from the general population. The 10-year CV risk was log-transformed, and multivariable linear regression was used to estimate mean ratios, adjusting for age, and education.

Results

Three hundred patients and 3,052 controls were included in the analysis. Among men, the 10-year CV risk score was very similar between patients with SMI and the general population (mean ratio [MR]: 1.02; 95%CI 0.77–1.37), whereas a 39% increase in 10-year CV risk was observed in women with SMI compared to the general population (MR: 1.39; 95%CI 1.16–1.66).

Conclusions

In our study, women with SMI were consistently more at risk than the general population counterpart, even at younger age.

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2020. Published by Cambridge University Press on behalf of the European Psychiatric Association

Introduction

Cardiovascular (CV) diseases are the leading cause of death and disability in Western countries. Patients with severe mental illnesses (SMIs) are twice as affected by obesity, diabetes, and metabolic syndrome than the general population and, accordingly, are at similarly increased risk of death due to CV disorders [Reference Correll, Solmi, Veronese, Bortolato, Rosson and Santonastaso1].

In the last 10 years, the concept of metabolic syndrome as a risk factor for CV diseases has acquired popularity, and many studies showed elevated rates of metabolic syndrome in patients with SMI compared to the general population [Reference Vancampfort, Stubbs, Mitchell, De Hert, Wampers and Ward2]. Metabolic syndrome is a pathological entity that identifies a group of people at very high risk for developing CV diseases over time. On the other hand, the use of tools providing an index of risk based on general factors such as age, gender, smoke habits, and lipid levels appears more useful in order to put in place behavioral and nonbehavioral strategies aimed at preventing the occurrence of CV events. For this reason starting from the landmark Framingham study, many others have assessed the 10-year risk of CV diseases in the general populations and in specific subpopulations.

In the last few years, the 10-year CV risk has eventually been assessed in subjects suffering from psychiatric disorders, especially patients with SMI, who are prescribed complex medication regimens, are more prone to inactivity and unhealthy dietary habits independently from socioeconomic status and are likely share genetic factors increasing their vulnerability to metabolic disorders. The majority of reports carried to assess the 10-year CV risk in patients with SMI compared to their reference populations found an increased relative risk of 1.5 in patients with SMI [3–8].

However, results from these studies have limited heuristic value for two main reasons. First, although conducted in Asian, European, and North American countries, they all employed the Framingham risk score algorithm, which was validated on the population of Framingham, USA, several decades ago. In recent years, there has been mounting evidence that the Framingham model overestimates the risk of developing CV disease, especially in high-risk individuals and European populations [Reference Damen, Pajouheshnia, Heus, Moons, Reitsma and Scholten9]. Accordingly, risk scores in patients and controls should be calculated employing an algorithm of risk validated on the reference population. Second, patients with SMI usually develop metabolic risk factors well before the general population [Reference Salvi, D'Ambrosio, Rosso, Bogetto and Maina10,Reference Emmerink, Bakker, Van Bemmel, Noorthoorn and Naarding11]; therefore, a rough estimate of CV risk in a whole sample of patients is of little utility in order to put in place preventive strategies. To this end, risk score calculations in different age groups are needed.

In this study, we aimed to assess the 10-year CV risk in a sample of North Italian patients with SMI stratified by sex and age compared with data from the general population. To do this, we employed a 10-year CV risk algorithm validated on the Italian population.

Methods

Study design

The study is a cross-sectional investigation of CV risk factors and estimated 10-year CV risk in patients with SMI compared with data from the Italian general population. The protocol was reviewed and approved by the relevant Ethical Committees (Comitato Etico Milano Area 1, Milan; Comitato Etico Ospedale San Martino, Genoa). To participate, patients had to sign a written informed consent.

Patients

Patients with SMI consecutively admitted to the psychiatric acute care units of Fatebenefratelli hospital, Milan, and San Martino hospital, Genoa, from May 2017 to April 2018 were recruited.

SMI was defined as having either schizophrenia or bipolar disorder. Patients were evaluated and diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [12]. For the sake of comparing patients’ data with those from the general population, only those aged 35–69 years were considered for the present study.

Patients were administered a questionnaire to assess sociodemographic and clinical characteristics such as age, gender, education, marital and occupational status, diagnosis, age at onset, number of episodes, presence of lifetime suicide attempts, and current pharmacological treatment. During the index hospitalization, weight, height, and blood pressure were measured. A blood examination assessing fasting glucose, total and high-density lipoprotein (HDL) cholesterol, and triglycerides, was performed. Lifestyles such as current smoking habits and physical exercise were also collected. Physical exercise was classified as absent, mild (<4 h/week), moderate (around 4 h/week), and intense (> 4 h/week).

Educational level was selected as a proxy for socioeconomic position; social class was characterized as primary/middle school (≤8 years; lower education) and high school/university degree (>8 years; higher education).

Reference population

Data on the reference population (individuals aged 35–69 years and resident in Northern Italy from 2008 to 2012) were obtained from the Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey (OEC/HES). The OEC/HES is part of the CUORE Project, launched by the Italian Ministry of Health and coordinated by the Department of Cardiovascular, Endocrine-metabolic Diseases, and Aging of the Italian National Insitute of health (Istituto Superiore di Sanità- ISS) that provided data for the present analyses.

The CUORE Project monitors CV risk factors, lifestyles, and diseases through different sources of information (population-based registries, longitudinal observational studies, risk assessment by general practitioners, and cross-sectional surveys) to produce a global picture of the population’s health and to identify priority areas for treatment and preventive actions [Reference Giampaoli, Palmieri, Donfrancesco, Lo Noce, Pilotto and Vanuzzo13].

The 10-year CV risk score from the general population of Northern Italian regions, based on risk factors collected within the OEC/HES 2008–2012 survey, was considered stratified by gender, age, and educational level groups.

10-year CV risk assessment

To assess CV risk, we employed the same algorithm developed within the CUORE Project [Reference Palmieri, Panico, Vanuzzo, Ferrario, Pilotto and Sega14,Reference Giampaoli, Palmieri, Donfrancesco, Panico, Vanuzzo and Pilotto15] and applied to OEC/HES participants [Reference Giampaoli, Palmieri, Donfrancesco, Lo Noce, Pilotto and Vanuzzo13]. The CUORE Project 10-year CV risk algorithm is based on the combination of seven risk factors (age, systolic blood pressure, total and HDL cholesterol, diabetes, smoking habit, and hypertensive treatment) and predicts 10-year fatal, and nonfatal coronary and cerebrovascular incidence [Reference Palmieri, Panico, Vanuzzo, Ferrario, Pilotto and Sega14,Reference Giampaoli, Palmieri, Donfrancesco, Panico, Vanuzzo and Pilotto15]. To assess the relation of risk factors, considered together, to the 10-year CV disease risk, multivariate analyses were performed. Starting from a basic Cox model that included age, systolic blood pressure, and dichotomic smoke habit, the other CV risk factor variables, when statistically significant in the univariate analyses and not presenting multicollinearity with the other variables in the model under study, were progressively included. The 10-year CV disease individual risk score models were implemented including continuous values of risk factors when available. All multivariate models were evaluated for accuracy by assessing the area under the receiver operating characteristic curve and performing Hosmer-Lemeshow test [Reference Giampaoli, Palmieri, Donfrancesco, Panico, Vanuzzo and Pilotto15].

Statistical analyses

Means and standard deviations were used to describe continuous variables, and counts and percentages were used for categorical variables. The mean levels of CV risk factors were sex- and age-standardized using the age structure of the general population, aged 35–69 years, resident in the Northern Italian regions in 2010. As a preliminary analysis showed that the difference of CV risk score between the two groups was constant among the different age groups on the multiplicative but not on the additive scale, CV risk score was log-transformed, and multivariable linear regression was used to estimate mean ratios, adjusting for age, and education.

Analyses were performed using Stata 15 Software (Stata Corp, College Station, TX).

Results

A total of 300 patients and 3,052 controls from the general population of Northern Italy were included in the study.

Mean age was comparable between patients and controls in both sexes. Gender was evenly distributed in patients and controls. Sociodemographic and clinical variables are shown in Table 1. Looking at CV risk factors, both men and women with SMI had higher triglycerides, lower HDL cholesterol levels, and smoked more cigarettes/day than controls. On the other hand, men and women from the general population had higher total cholesterol levels than patients. Males from control group also showed higher systolic blood pressure than female patients. CV risk factors in patients and controls are shown in Table 2.

Table 1. Sociodemographic and clinical characteristics of patients with severe mental illness.

Abbreviation: SD, standard deviation.

Table 2. Cardiovascular risk factors in patients and controls.

All variables were age-standardized using the age structure of the general population * in smokers.

Abbreviations: CV, cardiovascular; sd, standard deviation.

Among men, the 10-year CV risk score was very similar between patients with SMI and the general population (mean ratio [MR]: 1.02; 95%CI 0.77–1.37) (Figure 1 and Table 3). On the opposite, compared to the general population, women with SMI had a 39% increase in 10-year CV risk (MR: 1.39; 95%CI 1.16–1.66). Such an increase was evident in all age classes (Figure 2). These findings did not change after adjusting for participants’ educational level in both sexes (Table 3).

Figure 1. Ten-year cardiovascular risk in patients with severe mental illness compared to the general population. Men.

Table 3. Adjusted 10-year cardiovascular risk in patients with severe mental illness and controls.

a Adjusted by age.

b Adjusted by age and education.

Figure 2. Ten-year cardiovascular risk in patients with severe mental illness compared to the general population. Women.

Discussion

In this study, we assessed 10-year CV risk in patients with SMI and compared it with a large sample from the general population dwelling in the same regions. To this end, we grouped patients and controls according to sex and age, which are the main drivers of CV risk, being CV morbidity higher in the elderly and males [Reference Mozaffarian, Benjamin, Go, Arnett, Blaha and Cushman16].

As expected, the analyses showed that the estimated CV risk increases with age in both sexes. Educational level is a proxy for socioeconomic status, a sociodemographic factor known to influence CV risk; plus, well-educated people are more informed and more frequently follow guidelines and medical advice. The previously reported OEC/HES study conducted in Italy reported a small but significant reduction in CV risk factors in patients with a higher educational level [Reference Giampaoli, Palmieri, Donfrancesco, Lo Noce, Pilotto and Vanuzzo13]. Therefore, we adopted the same cutoffs and controlled our results for educational level, which, however, did not affect the results: the estimated CV risk was comparable in SMI patients with low or high educational attainment.

The vast majority of published studies have assessed the 10-year CV risk through the Framingham risk algorithm [4–8,17–19]. However, in a prospective study aimed at validating several risk algorithms on the UK population, the use of the Framingham algorithm overestimated CV risk in subjects with SMI, especially in males [Reference Osborn, Hardoon, Omar, Holt, King and Larsen20]. The inaccurate risk prediction may reflect differences between historical North American people and contemporary individuals from other countries; since by the time the Framingham model was developed, CV risk factors such as hypercholesterolemia or hypertension were not routinely treated, eventually leading to a higher number of CV events over time [Reference Damen, Pajouheshnia, Heus, Moons, Reitsma and Scholten9]. For these reasons, the authors recommended the preferable use of CV risk algorithms validated on the local general population. In keeping with this suggestion, we employed the CUORE Project algorithm [Reference Palmieri, Panico, Vanuzzo, Ferrario, Pilotto and Sega14,Reference Giampaoli, Palmieri, Donfrancesco, Panico, Vanuzzo and Pilotto15] that was applied also to OEC/HES participants [Reference Giampaoli, Palmieri, Donfrancesco, Lo Noce, Pilotto and Vanuzzo13].

The main finding of our study is the 40% increase in estimated CV risk in women with SMI compared with women from the general population. In fact, in our sample, women with SMI were consistently more at risk than their general population counterpart, even at younger ages. Similar results were found in the CATIE study, where the mean 10-year risk of coronary heart disease morbidity was 9.4% in males and 6.3% in females, yet a 50% increase of relative risk was found in females with schizophrenia compared to 34% in males [Reference Goff, Sullivan, McEvoy, Meyer, Nasrallah and Daumit5]. The results are also in line with the findings from a recent Scottish retrospective cohort study in which, aside from a generally higher incidence in males, the relative risk of ischemic heart disease and stroke associated with schizophrenia, bipolar disorders, or major depressive disorders was larger in females [Reference Jackson, Kerssens, Fleetwood, Smith, Mercer and Wild21].

Patients with SMI frequently adopt at-risk lifestyles, such as unhealthy eating, low physical activity, or absence thereof [Reference De Rosa, Sampogna, Luciano, Del Vecchio, Pocai and Borriello22,Reference Stubbs, Vancampfort, Hallgren, Firth, Veronese and Solmi23]. Moreover, the use of psychotropic medications, especially second-generation antipsychotics but also some mood stabilizers and anti-histaminergic antidepressants, further increases the incidence of obesity and other metabolic issues, leading to CV morbidity and mortality [24–26]. Lastly, due to their reduced access to medical care, key CV risk factors remain underscreened and undertreated in this population. The importance of a proper CV screening was made clear by Crump et al. study, in which the association between bipolar disorder and CV mortality was weaker in patients with a prior CV diagnosis, whereas in those without a prior CV diagnosis, the risk CV death was higher [Reference Crump, Sundquist, Winkleby and Sundquist27].

Beyond general risk factors, there is evidence that gender-related specific factors play a role. Exogenous hormone use such as contraceptive pills showed to increase the risk of myocardial infarction and stroke [Reference Roach, Helmerhorst, Lijfering, Stijnen, Algra and Dekkers28], and hormone replacement therapy in postmenopausal women increases stroke risk by about one-third [Reference Henderson and Lobo29]. Finally, women are less likely to receive guidance regarding preventive treatments, such as healthy behavior changes, lipid-lowering therapy, and aspirin use [Reference Kandasamy and Anand30].

In our sample, the effect of SMI on estimated CV risk was higher among women, independently from educational level. Looking at the risk profile, females with SMI displayed higher triglycerides and lower HDL cholesterol levels than healthy individuals. They also smoked more cigarettes per day. On the contrary, other factors such as total cholesterol, glucose, and blood pressure were comparable in women with or without SMI. The concordance between these results and findings from the literature is extremely high, with matching results in European, North American, and Asian populations [Reference Cohn, Prud'homme, Streiner, Kameh and Remington4,6–8,Reference Clerici, Bartoli, Carretta, Crocamo, Bebbington and Carrà31,Reference Coello, Kjærstad, Stanislaus, Melbye, Faurholt-Jepsen and Woznica Miskowiak32], suggesting that these parameters are not primarily affected by factors related to mental illness.

Examining the risk profile in men with SMI, we found, akin to women, higher triglycerides, lower HDL cholesterol, and more cigarette smoking compared with the control group. However, the increased risk in males is likely offset by lower systolic blood pressure in patients with SMI. Several studies found lower blood pressure values in patients with schizophrenia and bipolar disorders compared with general population samples [Reference Cohn, Prud'homme, Streiner, Kameh and Remington4,Reference Clerici, Bartoli, Carretta, Crocamo, Bebbington and Carrà31,Reference Coello, Kjærstad, Stanislaus, Melbye, Faurholt-Jepsen and Woznica Miskowiak32]. In the most recent Danish study, the authors argued that the finding was surprising, since subjects in their healthy comparison group were blood donors and likely with a healthy lifestyle [Reference Coello, Kjærstad, Stanislaus, Melbye, Faurholt-Jepsen and Woznica Miskowiak32]. A tentative explanation may reside in the use of hypotensive medications: either first- or second-generation antipsychotics, particularly chlorpromazine, clozapine, or quetiapine, are associated with reduced blood pressure and orthostatic hypotension [Reference Gugger33].

This is a multicenter study investigating CV risk on a relatively large sample of patients with SMI. Since patients were consecutively recruited, selection bias seems unlikely. General population samples used as control group were drawn from the same Northern Italian regions of the patients, thus increasing the reliability and robustness of the findings. Furthermore, as noted above, the use of an algorithm already validated in the Italian general population likely improves the accuracy of this prediction. However, some potential limitations should be acknowledged. First, this study did not prospectively follow patients to assess incident CV outcomes; therefore, it simply provides an estimate of the CV risk, not assessing the actual risk. Second, likewise the Framingham CV risk tool, the CUORE project CV risk algorithm was validated on the general population without SMI; therefore, it may not accurately catch the effect of SMI-specific exposures on CV risk; it would be appropriate for general population risk assessment tools to incorporate specific mental health measures. Having selected only subjects between 35 and 69 years of age, we cannot infer on CV risk in young or old patients; therefore, the results may not be generalized to all patients with SMI. Finally, the cross-sectional design of the study does not allow inferences on the causal relationship between the variables; therefore, prospective studies are needed to tease out the relative contribution of lifestyle and psychotropic medications on CV risk.

Our finding of an increased estimated CV risk in women with SMI is of utmost relevance. CV disease accounts for one-third of all deaths among females worldwide [34]. CV morbidity has been on the rise especially in vulnerable populations, such as socially disadvantaged and marginalized women with low income, increased stress, or childhood adversities [Reference Kandasamy and Anand30].

CV risk is the main driver of the observed reduction in life expectancy in people with SMI [Reference Correll, Solmi, Veronese, Bortolato, Rosson and Santonastaso1]. Preventive strategies should include frequent monitoring, lifestyle interventions such as encouraging healthy eating and physical activity [Reference Sampogna, Fiorillo, Luciano, Del Vecchio, Steardo and Pocai35], and modifying psychopharmacological treatment by switching to medications with negligible effects on weight and metabolism. Being these strategies not easily accomplished by SMI patients, some ways to overcome difficulties may be the enforcement of mental health services with integrated care managers or allocating funds to implement lifestyle modification programs in community mental health centers.

Acknowledgments

This work was developed within the framework of the DINOGMI Department of Excellence of MIUR 2018-2022 (law 232/2016). We want to thank all personnel who helped collecting data at ASST Fatebenefratelli Sacco, Milan, and Ospedale San Martino Hospital, Genoa.

Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Conflicts of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study will be made available upon request to the authors.

References

Correll, CU, Solmi, M, Veronese, N, Bortolato, B, Rosson, S, Santonastaso, P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163180. doi: 10.1002/wps.20420.CrossRefGoogle ScholarPubMed
Vancampfort, D, Stubbs, B, Mitchell, AJ, De Hert, M, Wampers, M, Ward, PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339347. doi: 10.1002/wps.20252.CrossRefGoogle ScholarPubMed
McCreadie, RG. Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534539. doi: 10.1192/bjp.183.6.534.Google ScholarPubMed
Cohn, T, Prud'homme, D, Streiner, D, Kameh, H, Remington, G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753760. doi: 10.1177/070674370404901106.CrossRefGoogle ScholarPubMed
Goff, DC, Sullivan, LM, McEvoy, JP, Meyer, JM, Nasrallah, HA, Daumit, GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):4553. doi: 10.1016/j.schres.2005.08.010.CrossRefGoogle ScholarPubMed
Tay, YH, Nurjono, M, Lee, J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. Schizophr Res. 2013;147(1):187192. doi: 10.1016/j.schres.2013.03.023.CrossRefGoogle ScholarPubMed
Rekhi, G, Khyne, TT, Lee, J. Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia. Gen Hosp Psychiatry. 2016;43:4650. doi: 10.1016/j.genhosppsych.2016.09.005.CrossRefGoogle ScholarPubMed
Zhao, S, Xia, H, Mu, J, Wang, L, Zhu, L, Wang, A, et al. 10-year CVD risk in Han Chinese mainland patients with schizophrenia. Psychiatry Res. 2018;264:322326. doi: 10.1016/j.psychres.2018.04.020.CrossRefGoogle Scholar
Damen, JA, Pajouheshnia, R, Heus, P, Moons, KGM, Reitsma, JB, Scholten, RJPM, et al. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019;17(1):109doi: 10.1186/s12916-019-1340-7.CrossRefGoogle ScholarPubMed
Salvi, V, D'Ambrosio, V, Rosso, G, Bogetto, F, Maina, G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65(1):4754. doi: 10.1111/j.1440-1819.2010.02160.x.CrossRefGoogle ScholarPubMed
Emmerink, D, Bakker, S, Van Bemmel, T, Noorthoorn, EO, Naarding, P. Skin autofluorescence assessment of cardiovascular risk in people with severe mental illness. BJPsych Open. 2018;4(4):313316. doi: 10.1192/bjo.2018.34.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing, 2013.Google Scholar
Giampaoli, S, Palmieri, L, Donfrancesco, C, Lo Noce, C, Pilotto, L, Vanuzzo, D. Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey Research Group. Cardiovascular health in Italy. Ten-year surveillance of cardiovascular diseases and risk factors: Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey 1998-2012. Eur J Prev Cardiol. 2015;22(2 Suppl):937. doi:10.1177/2047487315589011CrossRefGoogle Scholar
Palmieri, L, Panico, S, Vanuzzo, D, Ferrario, M, Pilotto, L, Sega, R. La valutazione del rischio cardiovascolare globale assoluto: il punteggio individuale del Progetto CUORE [Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score]. Ann Ist Super Sanita. 2004;40(4):393–9.Google Scholar
Giampaoli, S, Palmieri, L, Donfrancesco, C, Panico, S, Vanuzzo, D, Pilotto, L, et al. Cardiovascular risk assessment in Italy: the CUORE Project risk score and risk chart. Ital J Public Health. 2007;4:102109.Google Scholar
Mozaffarian, D, Benjamin, EJ, Go, AS, Arnett, DK, Blaha, MJ, Cushman, M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29e322. doi: 10.1161/CIR.0000000000000152.Google Scholar
Bobes, J, Arango, C, Aranda, P, Carmena, R, Garcia-Garcia, M, Rejas, J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90(1–3):162173. doi: 10.1016/j.schres.2006.09.025.CrossRefGoogle ScholarPubMed
Margari, F, Lozupone, M, Pisani, R, Pastore, A, Todarello, O, Zagaria, G, et al. Metabolic syndrome: differences between psychiatric and internal medicine patients. Int J Psychiatry Med. 2013;45(3):203226. doi: 10.2190/PM.45.3.a.CrossRefGoogle ScholarPubMed
Ratliff, JC, Palmese, LB, Reutenauer, EL, Srihari, VH, Tek, C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics. 2013;54(1):6773. doi: 10.1016/j.psym.2012.03.001.CrossRefGoogle ScholarPubMed
Osborn, DP, Hardoon, S, Omar, RZ, Holt, RI, King, M, Larsen, J, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry. 2015;72(2):143151. doi: 10.1001/jamapsychiatry.2014.2133.CrossRefGoogle ScholarPubMed
Jackson, CA, Kerssens, J, Fleetwood, K, Smith, DJ, Mercer, SW, Wild, SH. Incidence of ischaemic heart disease and stroke among people with psychiatric disorders: retrospective cohort study. Br J Psychiatry. 2019;217:442449. doi: 10.1192/bjp.2019.250.CrossRefGoogle Scholar
De Rosa, C, Sampogna, G, Luciano, M, Del Vecchio, V, Pocai, B, Borriello, G, et al. Improving physical health of patients with severe mental disorders: a critical review of lifestyle psychosocial interventions. Expert Rev Neurother. 2017;17(7):667681. doi: 10.1080/14737175.2017.1325321.CrossRefGoogle ScholarPubMed
Stubbs, B, Vancampfort, D, Hallgren, M, Firth, J, Veronese, N, Solmi, M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018;54:124144. doi: 10.1016/j.eurpsy.2018.07.004.CrossRefGoogle Scholar
Musil, R, Obermeier, M, Russ, P, Hamerle, M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):7396. doi: 10.1517/14740338.2015.974549.CrossRefGoogle ScholarPubMed
Salvi, V, Barone-Adesi, F, D'Ambrosio, V, Albert, U, Maina, G. High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder. Psychopharmacology (Berlin). 2016;233(1):4956. doi: 10.1007/s00213-015-4085-9.CrossRefGoogle ScholarPubMed
Grootens, KP, Meijer, A, Hartong, EG, Doornbos, B, Bakker, PR, Al Hadithy, A, et al. Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder. Eur J Clin Pharmacol. 2018;74(11):14851489. doi: 10.1007/s00228-018-2517-2.CrossRefGoogle ScholarPubMed
Crump, C, Sundquist, K, Winkleby, MA, Sundquist, J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70(9):931–9. doi:10.1001/jamapsychiatry.2013.1394, PMID:23863861CrossRefGoogle ScholarPubMed
Roach, RE, Helmerhorst, FM, Lijfering, WM, Stijnen, T, Algra, A, Dekkers, OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054doi: 10.1002/14651858.CD011054.pub2.Google Scholar
Henderson, VW, Lobo, RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric. 2012;15(3):229234. doi: 10.3109/13697137.2012.656254.CrossRefGoogle ScholarPubMed
Kandasamy, S, Anand, SS. Cardiovascular disease among women from vulnerable populations: a review. Can J Cardiol. 2018;34(4):450457. doi: 10.1016/j.cjca.2018.01.017.CrossRefGoogle ScholarPubMed
Clerici, M, Bartoli, F, Carretta, D, Crocamo, C, Bebbington, P, Carrà, G. Cardiovascular risk factors among people with severe mental illness in Italy: a cross-sectional comparative study. Gen Hosp Psychiatry. 2014;36(6):698702. doi: 10.1016/j.genhosppsych.2014.08.005.CrossRefGoogle ScholarPubMed
Coello, K, Kjærstad, HL, Stanislaus, S, Melbye, S, Faurholt-Jepsen, M, Woznica Miskowiak, K, et al. Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Aust N Z J Psychiatry. 2019;53(7):651662. doi: 10.1177/0004867418815987.CrossRefGoogle ScholarPubMed
Gugger, JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659671. doi: 10.2165/11591710-000000000-00000.CrossRefGoogle ScholarPubMed
Women and Heart Disease Facts. Women’s heart foundation, 2017. https://www.womensheart.org/content/heartdisease/heart_disease_facts.asp [accessed 15 June 2020].Google Scholar
Sampogna, G, Fiorillo, A, Luciano, M, Del Vecchio, V, Steardo, L, Pocai, B, et al. A randomized controlled trial on the efficacy of a psychosocial behavioural intervention to improve the lifestyle of patients with severe mental disorders: study protocol. Front Psychiatry. 2018;9:235. doi:10.3389/fpsyt.2018.00235CrossRefGoogle Scholar
Figure 0

Table 1. Sociodemographic and clinical characteristics of patients with severe mental illness.

Figure 1

Table 2. Cardiovascular risk factors in patients and controls.

Figure 2

Figure 1. Ten-year cardiovascular risk in patients with severe mental illness compared to the general population. Men.

Figure 3

Table 3. Adjusted 10-year cardiovascular risk in patients with severe mental illness and controls.

Figure 4

Figure 2. Ten-year cardiovascular risk in patients with severe mental illness compared to the general population. Women.

Submit a response

Comments

No Comments have been published for this article.